Zeke Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Zeke Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.01M	Sell	6,972 -562	-7%	-$171K	0.13%	72
2022 Q3	$2.18M	Buy	7,534 +5	+0.1%	+$1.44K	0.16%	66
2022 Q2	$2.12M	Sell	7,529 -1,233	-14%	-$330K	0.14%	71
2022 Q1	$2.29M	Buy	8,762 +1,322	+18%	+$314K	0.12%	85
2021 Q4	$1.63M	Buy	7,440 +279	+4%	+$54.3K	0.1%	69
2021 Q3	$1.3M	Buy	+7,161	New	+$1.4M	0.08%	83
2020 Q1	–	Sell	-2,179	Closed	-$477K	–	503
2019 Q4	$477K	Sell	2,179 -13	-0.6%	-$2.63K	0.04%	389
2019 Q3	$371K	Sell	2,192 -1,210	-36%	-$214K	0.03%	413
2019 Q2	$624K	Sell	3,402 -24	-0.7%	-$4.2K	0.06%	301
2019 Q1	$630K	Buy	3,426 +7	+0.2%	+$1.29K	0.06%	310
2018 Q4	$567K	Sell	3,419 -132	-4%	-$22.9K	0.05%	313
2018 Q3	$684K	Sell	3,551 -946	-21%	-$168K	0.06%	324
2018 Q2	$764K	Sell	4,497 -53	-1%	-$8.22K	0.07%	233
2018 Q1	$742K	Buy	4,550 +2,269	+99%	+$371K	0.07%	254
2017 Q4	$342K	Sell	2,281 -720	-24%	-$107K	0.04%	364
2017 Q3	$456K	Buy	3,001 +887	+42%	+$134K	0.06%	242
2017 Q2	$272K	Buy	+2,114	New	+$254K	0.05%	216

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Zeke Capital Advisors's VRTX Position: Q4 2022 in Review

Zeke Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 7.5% in Q4 2022, selling an estimated $171K and leaving 6,972 shares worth $2.01M. The position accounts for 0.13% of the portfolio, ranked #72.

Zeke Capital Advisors first reported a position in VRTX in Q2 2017 and has held it in 17 quarters since. The position peaked at $2.29M in Q1 2022. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Zeke Capital Advisors held 6,972 shares of Vertex Pharmaceuticals worth $2.01M as of Q4 2022.
Zeke Capital Advisors sold 562 Vertex Pharmaceuticals shares in Q4 2022, an estimated $171K.
Vertex Pharmaceuticals made up 0.13% of Zeke Capital Advisors's portfolio in Q4 2022, its #72 holding.
Zeke Capital Advisors first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 17 quarters since.
Zeke Capital Advisors's Vertex Pharmaceuticals position peaked at $2.29M in Q1 2022.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.